According to the report published by Market Research Store, global demand for the age related macular degeneration market was estimated at approximately USD 8,300 Million in 2019 and is anticipated to generate revenue of around USD 14,100 Million by end of 2026, growing at a CAGR of around 7.8% between 2020 and 2026.

Global Age Related Macular Degeneration Market: Overview

Macular degeneration, ARMD, or AMD are all terms for age-related macular degeneration. AMD is a retinal condition that causes blurring of central vision, which is essential for tasks such as driving, using a keyboard, watching tv, sewing, and reading that include looking straight ahead. The macula, a portion of the retina that helps you to see fine details, is impaired by AMD. AMD is a progressive eye condition that is painless. It is most common in patients over the age of 50.

Wet macular degeneration and dry macular degeneration are the two types of AMD. The first kind of AMD is the more serious of the two. It induces irregular blood flow progression in the affected region of the macula, impairing retinal vision. Though AMD is linked to aging, the study suggests that the disorder may also have a genetic aspect. Scientists from Duke University and other institutions have discovered a close connection between AMD production and the presence of gene variants such as complement factor H. (CFH). Nearly half of the potentially blinding cases of AMD are diagnosed with CFH gene deficiency. Variants of an additional gene, complement factor B, have been discovered to be active in the production of AMD by researchers at the University of Columbia Medical Center and others. A rare variation of these genes, which plays a crucial role in human immune responses, was discovered in about 74 percent of AMD patients surveyed. There is currently no cure for dry AMD; however, existing treatments may help to prolong the onset of vision loss and wet AMD.

Global Age Related Macular Degeneration Market: Growth Factors

Over the projected period, the demand for age-related macular degeneration is predicted to be driven by an increase in the geriatric population. According to the World Population Prospects report from 2017, the global population over 60 years old was 962 million, with a projected increase to about 2.1 billion by 2050. Globally, the population of people aged 60 and over is growing at a higher rate than all other age classes. This population is particularly vulnerable to age-related diseases such as diabetes, renal insufficiency, asthma, and macular degeneration. People between the ages of 50 and 59 have a 2% chance of developing advanced age-related macular degeneration, while those above the age of 75 have a 30% chance. Furthermore, over the projected period, the rising prevalence of age-related macular degeneration is anticipated to accelerate growth. As per the BrightFocus Foundation in January 2019, macular degeneration is the main cause of blindness in the U.S. population over 60 years old, with about 11 million people affected, with the number projected to double to almost 22 million by 2050.

Global Age Related Macular Degeneration Market: Segmentation

Age related macular degeneration market is segmented in terms of product type, drug type, route of administration, age group type, and end-user. Based on the product type, the market is divided into dry AMD and wet AMD. Wet AMD is caused by premature growth of blood vessels under the macula, while dry AMD is caused by the development of deposits called under the retina. Wet AMD has a greater market share than dry AMD due to the higher incidence of wet AMD in the geriatric community. The growing geriatric population around the world is driving up demand for wet macular degeneration treatments. According to a survey by the World Health Organization (WHO), the number of elderly people (those aged 60 and up) is predicted to rise to 21.1 percent by 2050. In 2050, the global population of elderly people is expected to exceed 2 billion. Both of these figures indicate that there will be a strong need for drugs to combat wet macular degeneration in the future. The demand is growing due to technical advances in macular degeneration care and adequate payment conditions. Based on the route of administration, the market is split into intravitreal and intravenous. The intravitreal segment is anticipated to gain market share because targeted drug distribution makes it more competitive. In addition, the majority of anti-VEGF injections are given intravitreal or intraocularly. On the basis of end-user analysis, the market is bifurcated into hospitals & clinics, academic research institutes, and diagnostic centers. In terms of revenue, the most common end-user category is hospitals and clinics. This is due to increased exposure to global trends, increasing disposable incomes, and changing lifestyles, which are among the common reasons for an increase in the number of visits to these institutes, as well as the number of procedures performed. The needed procedures are performed in a sterile environment and do not necessitate a long time of waiting or recovery. Based on age group type, the market is divided between 40 - 50 years, between 50 - 60 years, between 60 - 70 years, and above 70 years. The global population over 60 years old was 962 million in 2017, according to World Population Prospects, and is projected to hit around 2.1 billion by 2050. Globally, the population of people aged 60 and over is growing at a higher rate than all other age classes. This population is particularly vulnerable to age-related diseases such as diabetes, renal insufficiency, asthma, and macular degeneration. People between the ages of 50 and 59 have a 2% chance of developing advanced age-related macular degeneration, while those above the age of 75 have a 30% chance.

Global Age Related Macular Degeneration Market: Regional Analysis

In North America, the aesthetic equipment industry has evolved rapidly over the last two decades. Technological advancements in devices, growing knowledge of cosmetic procedures, rising acceptance of minimally invasive devices, and an increase in the obese population in the area are all projected to positively impact the studied market's development. There were 18.1 million cosmetic operations performed in 2019, up 2% from 2018, including 1.8 million cosmetic surgical procedures and 16.3 million cosmetic minimally medical interventions, according to the data shared by the American Society of Plastic Surgeons. In addition, the region's high concentration of global players, as well as subsequent product releases, play an important role in the region's market development. For example, Essence Group's E.S.I. company, released JOLI360, a revolutionary facial rejuvenation treatment that can calculate three skin factors: hydration, elasticity, and sebum, in June 2020. As a result, the above factors are projected to fuel the demand in North America over the forecast period.

Global Age Related Macular Degeneration Market: Competitive Players

The major players dominating the global age related macular degeneration market in terms of revenue and development are Valeant Pharmaceuticals International, Inc., Novartis International AG, Ophthotech Corporation, Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd, Bayer AG, Adverum Biotechnologies, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., Gilead Sciences Inc., Apellis Pharmeceuticals, Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Neurotech Pharmaceuticals Inc., and Alimera Sciences Inc., and Others. These international companies have used a number of tactics to create a credible presence in the global economy, including purchasing relationships, shares, arrangements, collaborations, joint ventures, new product launches, revenues, and mergers and acquisitions. In July 2017, Ophthotech Corporation announced that it would develop treatments for a number of orphan ophthalmic diseases based on clinical practice and retina expertise. In December 2016, EyeMedics, LLC and Acucela agreed to collaborate on research and development. In September 2017, F. Hoffmann-La Roche AG announced the first lampalizumab phase III trial for geographic atrophy caused by AMD.

Age Related Macular Degeneration Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1 Executive Summary
    • 1.1. Introduction of Age Related Macular Degeneration
    • 1.2. Global Age Related Macular Degeneration Market, 2019 & 2026 (USD Million)
    • 1.3. Global Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 1.4. Global Age Related Macular Degeneration Market Absulute Revenue Opportunity, 2016 – 2026 (USD Million)
    • 1.5. Global Age Related Macular Degeneration Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
  • Chapter 2 Age Related Macular Degeneration Market – Product Type Analysis
    • 2.1. Global Age Related Macular Degeneration Market – Product Type Overview
    • 2.2. Global Age Related Macular Degeneration Market Share, by Product Type, 2019 & 2026 (USD Million)
    • 2.3. Dry AMD
      • 2.3.1. Global Dry AMD Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 2.4. Wet AMD
      • 2.4.1. Global Wet AMD Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 3 Age Related Macular Degeneration Market – Drug Type Analysis
    • 3.1. Global Age Related Macular Degeneration Market – Drug Type Overview
    • 3.2. Global Age Related Macular Degeneration Market Share, by Drug Type, 2019 & 2026 (USD Million)
    • 3.3. Eylea
      • 3.3.1. Global Eylea Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 3.4. Lucentis
      • 3.4.1. Global Lucentis Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 3.5. Avastin
      • 3.5.1. Global Avastin Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 3.6. Others
      • 3.6.1. Global Others Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 4 Age Related Macular Degeneration Market – Age Group Type Analysis
    • 4.1. Global Age Related Macular Degeneration Market – Age Group Type Overview
    • 4.2. Global Age Related Macular Degeneration Market Share, by Age Group Type, 2019 & 2026 (USD Million)
    • 4.3. Between 40 - 50 Years
      • 4.3.1. Global Between 40 - 50 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 4.4. Between 50 - 60 Years
      • 4.4.1. Global Between 50 - 60 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 4.5. Between 60 - 70 Years
      • 4.5.1. Global Between 60 - 70 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 4.6. Above 70 Years
      • 4.6.1. Global Above 70 Years Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 5 Age Related Macular Degeneration Market – Route Of Administration Analysis
    • 5.1. Global Age Related Macular Degeneration Market – Route Of Administration Overview
    • 5.2. Global Age Related Macular Degeneration Market Share, by Route Of Administration, 2019 & 2026 (USD Million)
    • 5.3. Intravitreal
      • 5.3.1. Global Intravitreal Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 5.4. Intravenous
      • 5.4.1. Global Intravenous Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 6 Age Related Macular Degeneration Market – End-User Analysis
    • 6.1. Global Age Related Macular Degeneration Market – End-User Overview
    • 6.2. Global Age Related Macular Degeneration Market Share, by End-User, 2019 & 2026 (USD Million)
    • 6.3. Hospital & Clinics
      • 6.3.1. Global Hospital & Clinics Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 6.4. Academic Research Institutes
      • 6.4.1. Global Academic Research Institutes Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 6.5. Diagnostic Centers
      • 6.5.1. Global Diagnostic Centers Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 7 Age Related Macular Degeneration Market – Regional Analysis
    • 7.1. Global Age Related Macular Degeneration Market Regional Overview
    • 7.2. Global Age Related Macular Degeneration Market Share, by Region, 2019 & 2026 (USD Million)
    • 7.3. North America
      • 7.3.1. North America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
        • 7.3.1.1. North America Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
      • 7.3.2. North America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
        • 7.3.2.1. North America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
      • 7.3.3. North America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
        • 7.3.3.1. North America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
      • 7.3.4. North America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
        • 7.3.4.1. North America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
      • 7.3.5. North America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
        • 7.3.5.1. North America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
      • 7.3.6. North America Age Related Macular Degeneration Market, by End-User, 2016 – 2026
        • 7.3.6.1. North America Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
      • 7.3.7. U.S.
        • 7.3.7.1. U.S. Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.3.8. Canada
        • 7.3.8.1. Canada Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 7.4. Europe
      • 7.4.1. Europe Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
        • 7.4.1.1. Europe Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
      • 7.4.2. Europe Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
        • 7.4.2.1. Europe Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
      • 7.4.3. Europe Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
        • 7.4.3.1. Europe Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
      • 7.4.4. Europe Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
        • 7.4.4.1. Europe Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
      • 7.4.5. Europe Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
        • 7.4.5.1. Europe Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
      • 7.4.6. Europe Age Related Macular Degeneration Market, by End-User, 2016 – 2026
        • 7.4.6.1. Europe Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
      • 7.4.7. Germany
        • 7.4.7.1. Germany Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.4.8. France
        • 7.4.8.1. France Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.4.9. U.K.
        • 7.4.9.1. U.K. Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.4.10. Italy
        • 7.4.10.1. Italy Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.4.11. Spain
        • 7.4.11.1. Spain Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.4.12. Rest of Europe
        • 7.4.12.1. Rest of Europe Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 7.5. Asia Pacific
      • 7.5.1. Asia Pacific Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
        • 7.5.1.1. Asia Pacific Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
      • 7.5.2. Asia Pacific Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
        • 7.5.2.1. Asia Pacific Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
      • 7.5.3. Asia Pacific Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
        • 7.5.3.1. Asia Pacific Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
      • 7.5.4. Asia Pacific Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
        • 7.5.4.1. Asia Pacific Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
      • 7.5.5. Asia Pacific Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
        • 7.5.5.1. Asia Pacific Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
      • 7.5.6. Asia Pacific Age Related Macular Degeneration Market, by End-User, 2016 – 2026
        • 7.5.6.1. Asia Pacific Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
      • 7.5.7. China
        • 7.5.7.1. China Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.5.8. Japan
        • 7.5.8.1. Japan Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.5.9. India
        • 7.5.9.1. India Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.5.10. South Korea
        • 7.5.10.1. South Korea Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.5.11. South-East Asia
        • 7.5.11.1. South-East Asia Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.5.12. Rest of Asia Pacific
        • 7.5.12.1. Rest of Asia Pacific Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 7.6. Latin America
      • 7.6.1. Latin America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
        • 7.6.1.1. Latin America Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
      • 7.6.2. Latin America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
        • 7.6.2.1. Latin America Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
      • 7.6.3. Latin America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
        • 7.6.3.1. Latin America Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
      • 7.6.4. Latin America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
        • 7.6.4.1. Latin America Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
      • 7.6.5. Latin America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
        • 7.6.5.1. Latin America Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
      • 7.6.6. Latin America Age Related Macular Degeneration Market, by End-User, 2016 – 2026
        • 7.6.6.1. Latin America Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
      • 7.6.7. Brazil
        • 7.6.7.1. Brazil Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.6.8. Mexico
        • 7.6.8.1. Mexico Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.6.9. Rest of Latin America
        • 7.6.9.1. Rest of Latin America Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
    • 7.7. The Middle-East and Africa
      • 7.7.1. The Middle-East and Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
        • 7.7.1.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Country, 2016 - 2026 (USD Million)
      • 7.7.2. The Middle-East and Africa Age Related Macular Degeneration Market, by Product Type, 2016 – 2026
        • 7.7.2.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Product Type, 2016 – 2026 (USD Million)
      • 7.7.3. The Middle-East and Africa Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026
        • 7.7.3.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Drug Type, 2016 – 2026 (USD Million)
      • 7.7.4. The Middle-East and Africa Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026
        • 7.7.4.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Age Group Type, 2016 – 2026 (USD Million)
      • 7.7.5. The Middle-East and Africa Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026
        • 7.7.5.1. The Middle-East and Africa Age Related Macular Degeneration Market, by Route Of Administration, 2016 – 2026 (USD Million)
      • 7.7.6. The Middle-East and Africa Age Related Macular Degeneration Market, by End-User, 2016 – 2026
        • 7.7.6.1. The Middle-East and Africa Age Related Macular Degeneration Market, by End-User, 2016 – 2026 (USD Million)
      • 7.7.7. GCC Countries
        • 7.7.7.1. GCC Countries Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.7.8. South Africa
        • 7.7.8.1. South Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
      • 7.7.9. Rest of Middle-East Africa
        • 7.7.9.1. Rest of Middle-East Africa Age Related Macular Degeneration Market, 2016 – 2026 (USD Million)
  • Chapter 8 Age Related Macular Degeneration Market – Competitive Landscape
    • 8.1. Competitor Market Share – Revenue
    • 8.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    • 8.3. Strategic Developments
      • 8.3.1. Acquisitions and Mergers
      • 8.3.2. New Products
      • 8.3.3. Research & Development Activities
  • Chapter 9 Company Profiles
    • 9.1. Valeant Pharmaceuticals International, Inc.
      • 9.1.1. Company Overview
      • 9.1.2. Product/Service Portfulio
      • 9.1.3. Valeant Pharmaceuticals International, Inc. Sales, Revenue, and Gross Margin
      • 9.1.4. Valeant Pharmaceuticals International, Inc. Revenue and Growth Rate
      • 9.1.5. Valeant Pharmaceuticals International, Inc. Market Share
      • 9.1.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.2. Novartis International AG
      • 9.2.1. Company Overview
      • 9.2.2. Product/Service Portfulio
      • 9.2.3. Novartis International AG Sales, Revenue, and Gross Margin
      • 9.2.4. Novartis International AG Revenue and Growth Rate
      • 9.2.5. Novartis International AG Market Share
      • 9.2.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.3. Ophthotech Corporation
      • 9.3.1. Company Overview
      • 9.3.2. Product/Service Portfulio
      • 9.3.3. Ophthotech Corporation Sales, Revenue, and Gross Margin
      • 9.3.4. Ophthotech Corporation Revenue and Growth Rate
      • 9.3.5. Ophthotech Corporation Market Share
      • 9.3.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.4. Pfizer Inc.
      • 9.4.1. Company Overview
      • 9.4.2. Product/Service Portfulio
      • 9.4.3. Pfizer Inc. Sales, Revenue, and Gross Margin
      • 9.4.4. Pfizer Inc. Revenue and Growth Rate
      • 9.4.5. Pfizer Inc. Market Share
      • 9.4.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.5. Kubota Pharmaceutical Huldings Co. Ltd
      • 9.5.1. Company Overview
      • 9.5.2. Product/Service Portfulio
      • 9.5.3. Kubota Pharmaceutical Huldings Co. Ltd Sales, Revenue, and Gross Margin
      • 9.5.4. Kubota Pharmaceutical Huldings Co. Ltd Revenue and Growth Rate
      • 9.5.5. Kubota Pharmaceutical Huldings Co. Ltd Market Share
      • 9.5.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.6. Bayer AG
      • 9.6.1. Company Overview
      • 9.6.2. Product/Service Portfulio
      • 9.6.3. Bayer AG Sales, Revenue, and Gross Margin
      • 9.6.4. Bayer AG Revenue and Growth Rate
      • 9.6.5. Bayer AG Market Share
      • 9.6.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.7. Adverum Biotechnulogies, Inc.
      • 9.7.1. Company Overview
      • 9.7.2. Product/Service Portfulio
      • 9.7.3. Adverum Biotechnulogies, Inc. Sales, Revenue, and Gross Margin
      • 9.7.4. Adverum Biotechnulogies, Inc. Revenue and Growth Rate
      • 9.7.5. Adverum Biotechnulogies, Inc. Market Share
      • 9.7.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.8. Regeneron Pharmaceuticals, Inc.
      • 9.8.1. Company Overview
      • 9.8.2. Product/Service Portfulio
      • 9.8.3. Regeneron Pharmaceuticals, Inc. Sales, Revenue, and Gross Margin
      • 9.8.4. Regeneron Pharmaceuticals, Inc. Revenue and Growth Rate
      • 9.8.5. Regeneron Pharmaceuticals, Inc. Market Share
      • 9.8.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.9. Amgen Inc.
      • 9.9.1. Company Overview
      • 9.9.2. Product/Service Portfulio
      • 9.9.3. Amgen Inc. Sales, Revenue, and Gross Margin
      • 9.9.4. Amgen Inc. Revenue and Growth Rate
      • 9.9.5. Amgen Inc. Market Share
      • 9.9.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.10. Gilead Sciences Inc.
      • 9.10.1. Company Overview
      • 9.10.2. Product/Service Portfulio
      • 9.10.3. Gilead Sciences Inc. Sales, Revenue, and Gross Margin
      • 9.10.4. Gilead Sciences Inc. Revenue and Growth Rate
      • 9.10.5. Gilead Sciences Inc. Market Share
      • 9.10.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.11. Apellis Pharmeceuticals, Inc.
      • 9.11.1. Company Overview
      • 9.11.2. Product/Service Portfulio
      • 9.11.3. Apellis Pharmeceuticals, Inc. Sales, Revenue, and Gross Margin
      • 9.11.4. Apellis Pharmeceuticals, Inc. Revenue and Growth Rate
      • 9.11.5. Apellis Pharmeceuticals, Inc. Market Share
      • 9.11.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
      • 9.12. F. Hoffmann-La Roche Ltd.
      • 9.12.1. Company Overview
      • 9.12.2. Product/Service Portfulio
        • 9.12.3. F. Hoffmann-La Roche Ltd. Sales, Revenue, and Gross Margin
        • 9.12.4. F. Hoffmann-La Roche Ltd. Revenue and Growth Rate
        • 9.12.5. F. Hoffmann-La Roche Ltd. Market Share
      • 9.12.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.13. Bausch Health Companies Inc.
      • 9.13.1. Company Overview
      • 9.13.2. Product/Service Portfulio
      • 9.13.3. Bausch Health Companies Inc. Sales, Revenue, and Gross Margin
      • 9.13.4. Bausch Health Companies Inc. Revenue and Growth Rate
      • 9.13.5. Bausch Health Companies Inc. Market Share
      • 9.13.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.14. Neurotech Pharmaceuticals Inc.
      • 9.14.1. Company Overview
      • 9.14.2. Product/Service Portfulio
      • 9.14.3. Neurotech Pharmaceuticals Inc. Sales, Revenue, and Gross Margin
      • 9.14.4. Neurotech Pharmaceuticals Inc. Revenue and Growth Rate
      • 9.14.5. Neurotech Pharmaceuticals Inc. Market Share
      • 9.14.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.15. Alimera Sciences Inc.
      • 9.15.1. Company Overview
      • 9.15.2. Product/Service Portfulio
      • 9.15.3. Alimera Sciences Inc. Sales, Revenue, and Gross Margin
      • 9.15.4. Alimera Sciences Inc. Revenue and Growth Rate
      • 9.15.5. Alimera Sciences Inc. Market Share
      • 9.15.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 9.16. Others
      • 9.16.1. Company Overview
      • 9.16.2. Product/Service Portfulio
      • 9.16.3. Others Sales, Revenue, and Gross Margin
      • 9.16.4. Others Revenue and Growth Rate
      • 9.16.5. Others Market Share
      • 9.16.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
  • Chapter 10 Age Related Macular Degeneration — Industry Analysis
    • 10.1. Introduction and Taxonomy
    • 10.2. Age Related Macular Degeneration Market – Key Trends
      • 10.2.1. Market Drivers
      • 10.2.2. Market Restraints
      • 10.2.3. Market Opportunities
    • 10.3. Value Chain Analysis
    • 10.4. Key Mandates and Regulations
    • 10.5. Technulogy Roadmap and Timeline
    • 10.6. Age Related Macular Degeneration Market – Attractiveness Analysis
      • 10.6.1. By Product Type
      • 10.6.2. By Drug Type
      • 10.6.3. By Age Group Type
      • 10.6.4. By Route Of Administration
      • 10.6.5. By End-User
      • 10.6.6. By Region
  • Chapter 11 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    • 11.1. Age Related Macular Degeneration Industrial Chain Analysis
    • 11.2. Downstream Buyers
    • 11.3. Distributors/Traders List
  • Chapter 12 Marketing Strategy Analysis
    • 12.1. Marketing Channel
    • 12.2. Direct Marketing
    • 12.3. Indirect Marketing
    • 12.4. Marketing Channel Development Trends
    • 12.5. Economic/Pulitical Environmental Change
  • Chapter 13 Report Conclusion & Key Insights
    • 13.1. Key Insights from Primary Interviews & Surveys Respondents
    • 13.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  • Chapter 14 Research Approach & Methodulogy
    • 14.1. Report Description
    • 14.2. Research Scope
    • 14.3. Research Methodulogy
      • 14.3.1. Secondary Research
      • 14.3.2. Primary Research
      • 14.3.3. Statistical Models
        • 14.3.3.1. Company Share Analysis Model
        • 14.3.3.2. Revenue Based Modeling
      • 14.3.4. Research Limitations

Inquiry For Buying

Age Related Macular Degeneration

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Age Related Macular Degeneration

Please fill out the form. We will contact you within 24 hours:
All fields required...
Inquiry For Buying

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you


Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com
-->